Pharmacy Compounding Advisory Committee and peptides: the July 2026 votes and the February 2027 meeting

The Pharmacy Compounding Advisory Committee (PCAC) is the outside expert panel, required by law, that advises FDA on which bulk ingredients pharmacies may compound under section 503A, including peptides such as BPC-157 (PCAC charter). Its votes are advice, not law. On July 23–24, 2026 it backed six of seven peptides for the 503A Bulks List against FDA staff proposals; no peptide is on that list as of 2026-10-10, and the next peptide meeting is due before the end of February 2027.

Item	Status
What the PCAC is	FDA advisory committee required by sections 503A and 503B; advice only, FDA keeps “full regulatory decision-making authority” (charter)
US FDA status	A PCAC vote is not a drug approval; even after a 503A listing, the compounded product “is not FDA approved” (FDA, July 2026)
Compounding (503A)	PCAC voted on 2026-07-23/24 to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon and against emideltide (DSIP); advisory, no FDA rule yet. The 503A list holds six substances, none a peptide (21 CFR 216.23)
Next meeting	Before the end of February 2027: LL-37, GHK-Cu, dihexa acetate, Melanotan II, PEG-MGF; date not yet set (FDA)
WADA 2026	Unchanged by any PCAC vote; unapproved peptides not named elsewhere on the List, such as BPC-157, fall under S0 (USADA)
Strongest evidence	FDA briefing documents, meeting minutes and the Code of Federal Regulations (primary regulatory records)
Human trials	Not applicable: a regulatory process, not a treatment; FDA’s July 2026 reviews are linked below
Last checked	2026-10-10

What is the Pharmacy Compounding Advisory Committee?

The PCAC is a standing FDA committee that advises on “scientific, technical, and medical issues concerning drug compounding under sections 503A and 503B” of the Federal Food, Drug, and Cosmetic Act (FDA committee page). Section 503A covers state-licensed pharmacies and physicians compounding for an individual patient on a prescription; section 503B covers outsourcing facilities (FDA). Its core is 12 voting members, including the chair, drawn from compounding pharmacy, medicine, the National Association of Boards of Pharmacy, the US Pharmacopeia and patient and public-health groups; industry representatives may sit without a vote.

The committee exists because the law requires it: its charter cites 21 U.S.C. 353a(c)(1) and 353b(c)(2). The same charter says FDA “is not required to convene the Committee each calendar year,” lets FDA add temporary voting members for specialist topics, and states that the committee “provides advice and recommendations, but FDA retains full regulatory decision-making authority.” That is why a PCAC vote, however lopsided, changes nothing on its own.

How does a peptide get reviewed?

A 503A pharmacy may compound from a bulk ingredient only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List that FDA builds “through regulations” (FDA briefing introduction, July 2026). The peptides FDA has brought to the committee were nominated for that third route, the list.

FDA opened nominations for the list in 2015 (FDA 503A bulks page). For each nominated substance, a team from three FDA offices (compounding, new drugs and pharmaceutical quality) scores it on four criteria set by a 2019 rule, then weighs them against each other “on a substance-by-substance basis”:

• Characterization: whether the substance’s physical and chemical identity can be pinned down.
• Safety: safety issues raised by its use in compounded drugs.
• Effectiveness: the available evidence that a compounded product works, or does not.
• Historical use: how it has been compounded, for which conditions, with any peer-reviewed literature.

FDA’s July 2026 opening slides list those four criteria and that review team, and add a caution: “Information on dispensing or patient use is not the same thing as real-world data or clinical evidence” (FDA presentation). FDA then publishes a proposal for each substance, the nominator presents, the public comments through a docket, and the committee votes on a plain question such as “Should BPC-157 (free base) be placed on the list?” (FDA questions). Salt and free-base forms get separate votes.

What would a 503A listing mean?

A listing would let 503A pharmacies use a peptide as a bulk ingredient. It would not make the result an approved drug. FDA’s July 2026 presentation spelled out five consequences: the compounded product “is not FDA approved”; it “is not required to have a label to inform patients and providers how to use it”; it need not meet current good manufacturing practice, although the ban on insanitary conditions still applies; 503A compounders “are not required to report adverse events” to FDA; and, unless the entry is limited, the substance “can be compounded for any use or via any route of administration” (FDA presentation).

The regulation itself adds a warning. Under 21 CFR 216.23(d), FDA states there are “inadequate data to demonstrate the safety or efficacy” of drugs compounded from listed substances, and anyone presenting such a drug as FDA approved or endorsed makes it misbranded. A listing is a permission to compound, not a finding that the peptide works.

Peptide votes so far

Since 2024 the committee has voted on peptides at three meetings. The 2024 votes come from FDA’s final minutes; the July 2026 counts come from trade press and law-firm reports because FDA has posted no minutes.

Peptide (use reviewed)	Meeting	Vote to list (yes–no–abstain)
Ipamorelin, both forms (GHD, postoperative ileus)	2024-10-29	0–12–1 (minutes)
Kisspeptin-10 (secondary hypogonadism in men)	2024-10-29	0–11–0
CJC-1295, five forms (GHD)	2024-12-04	0–13 for four forms; 1–12 for the acetate (minutes)
AOD-9604, both forms (obesity)	2024-12-04	0–12–0
Thymosin alpha-1, both forms (hepatitis B and C, HIV, others)	2024-12-04	4–17–0
BPC-157 (ulcerative colitis)	2026-07-23	8–6–1, reported
KPV (wound healing, inflammation)	2026-07-23	8–6–1, reported
TB-500 (wound healing)	2026-07-23	8–6–1, reported
MOTS-c (obesity, osteoporosis)	2026-07-23	7–5–2, reported
Semax (cerebral ischemia, migraine)	2026-07-24	8–5, reported
Epitalon (insomnia)	2026-07-24	Majority yes; reports differ (7–4 or 7–5)
Emideltide / DSIP (insomnia, narcolepsy, opioid withdrawal)	2026-07-24	6–7, against

The 2024 meetings went the way FDA’s reviewers proposed. On kisspeptin-10, the October 2024 minutes record that the committee “unanimously agreed” it should not be listed “due to the lack of convincing safety and efficacy data,” and one member noted during the ipamorelin vote that how often a drug is prescribed “does not necessarily mean the drug is safe and effective.” Thymosin alpha-1 drew the most support of the 2024 peptides: some members who voted yes in December commented that it “should be accessible to patients as an option” (December 2024 minutes).

The July 2026 meeting: FDA proposed no, the committee said yes

The July 23–24, 2026 meeting reviewed seven peptides, each for named uses, with public comments taken under docket FDA-2025-N-6895 (FDA meeting page). Two facts in FDA’s briefing introduction shape how the votes should be read. First, every nomination, from Wells Pharmacy Network and from LDT Health Solutions on behalf of the International Peptide Society, “was withdrawn by the nominator,” yet “FDA is electing to proceed” with the review. Second, FDA proposed that all 14 forms, free base and acetate of each peptide, NOT be included on the list.

The committee broke with that position for six of the seven, as reported by trade press (STAT, AJMC) and the law firm McDermott Will & Emery; only emideltide failed. A detailed peptide-by-peptide reading is in our July 2026 PCAC vote explainer. FDA itself said it “does not intend to issue a final determination” until the committee’s input has been considered and its reviews finalized.

The February 2027 meeting: what is on the agenda

FDA has announced that it “will host an advisory committee meeting before the end of February 2027” on five more substances being considered for the 503A list: cathelicidin (LL-37), GHK-Cu, dihexa acetate, Melanotan II and pegylated mechano growth factor (PEG-MGF) (FDA early announcement). The time and place “will be scheduled in the coming months,” and FDA says a Federal Register notice and public docket will follow. A search of the Federal Register’s FDA notices on 2026-10-10 found no notice for that meeting yet; the latest PCAC notice is the one for July (2026-07361).

All five sit on FDA’s list of substances that were in Category 2, its “significant safety risks” group, until their nominations were withdrawn (FDA Category 2 page). For GHK-Cu, FDA’s concern applies to injectable routes: it cites possible immunogenicity from aggregation and impurities and “limited data in humans.” Several withdrawn peptides, including selank, CJC-1295, AOD-9604 and thymosin alpha-1, are on no announced 2027 agenda; the last three already had 2024 votes against listing. More on GHK-Cu is in our GHK-Cu entry.

What happens after a vote?

A favorable vote starts rulemaking; it does not end it. FDA adds substances to the 503A list only through notice-and-comment regulations (FDA 503A bulks page). The record shows how slow that can be: a February 2019 final rule placed six substances on the list and turned down four, and a September 2019 proposed rule to list five more and reject 26 is still described by FDA as awaiting a final regulation. The list in 21 CFR 216.23 today names brilliant blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide.

Meanwhile the interim category system is frozen for new entries: FDA does not intend to place substances nominated on or after January 7, 2025 into Categories 1, 2 or 3. Four peptides remain in Category 2, all added on September 29, 2023: GHRP-2, GHRP-6 and ipamorelin acetate for 503B, and kisspeptin-10 for 503A (FDA Category 2 page). How the categories and the two compounding pathways differ is set out in our guides to Category 1 vs Category 2 and 503A vs 503B.

Where semaglutide and other approved peptides fit

Searches for “semaglutide compounding pharmacy” concern a different rule. Semaglutide and tirzepatide are components of FDA-approved drugs, so the bulks list and the PCAC are not the question for 503A pharmacies; the limit is the ban on compounding “essentially copies of a commercially available drug product” regularly or in inordinate amounts (FDA GLP-1 compounding page). In its April 1, 2026 update FDA said it does not intend to act when a compounder fills four or fewer prescriptions of such a copy in a calendar month, and that tirzepatide and semaglutide “do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”

Safety: what FDA’s reviews flag

Most of the risks FDA lists for compounded peptides concern product quality and missing human data. Its Category 2 entries for peptides repeat the same concerns: possible immunogenicity (an immune reaction to the peptide or its impurities), aggregation, “peptide-related impurities” and difficulty characterizing the active ingredient; for TB-500, FDA “has not identified any human exposure data” (FDA Category 2 page). FDA also reminds the committee that compounded drugs are not reviewed “for safety, efficacy, or manufacturing quality before marketing” (FDA presentation). For athletes, no committee vote changes anti-doping rules: USADA names BPC-157 as an example of a non-approved substance prohibited under S0 (USADA). Products sold as “research use only” are a separate matter, covered in our research-use-only guide.